

Author index

Volume 4 1997

Adams DN, 731
Adams, SR, 867
Ahsen von, U, 357
Allemann, RK, 643
Arkin, MR, 389

Bailey, H, 497
Bailey, VC, 51
Baird, EE, 569
Baltz, RH, 195
Banerjee, R, 175
Banner, DW, 287
Barbone FP, 939
Bardsley, B, 507
Bartel, DP, 767
Barton, JK, 389
Bayle, JH, 885
Becker, JW, 149
Bemis, GW, 423
Beratan, DN, 3
Berlin, K, 63
Bertozzi, CR, 415
Bigger, SR, 961
Bird, MI, 543
Blackburn, JM, 481
Blanchard, SG, 909
Blanco, G, 751
Borchardt, A, 961, 961
Bolli, M, 309
Brack, A, 9
Braha, O, 497
Brown, A, 833
Brown, P, 909
Bruner, SD, 329
Burke, DH, 833

Cane, DE, 757
Caron, PR, 423
Casey, PJ, 711
Chapman, KT, 149
Chaput, JC, 899
Charlton, J, 809
Charlton, PS, 909
Cheley, S, 497
Chen, S, 859
Chuck, J, 757
Chung, JS, 105
Cleland, WW, 259
Coast, GM, 105
Codi, E, 357
Cohen, FE, 345
Collins, HW, 249
Copley, SD, 169

Cowan, JA, 513
Coward, JK, 859
Crabtree, GR, 885, 961

Dervan, PB, 569
Diederich, F, 287
Distefano, MD, 731
Dougherty, DA, 739
Drueckhammer, DG, 17

Eaton, BE, 675
Egli, M, 643
Ellington, AD, 595
Ellman, LA, 297
Encell, LP, 889
Eschenmoser, A, 309
Ewing, TJA, 297

Farrell, FX, 939
Famulok, M, 357
Fedor, MJ, 619
Freedy, J, 939
Fiala, R, 35
Fields, GB, 731
Fitzgibbon, MJ, 423
Fivush, A M, 909
Fortt, SM
Frey, PA, 259

Galione, A, 51
Gallivan, JP, 739
Galullo, V, 423
Gehring, AM, 17
Gerlt, JA, 259
Geyer, CR, 579
Gilson, MK, 87
Given, JA, 87
Gold, L, 833
Golomb, B, 651
González, JE, 269
Gouaux, JE, 497
Groves, JT, 845

Hager AJ, 607
Hakala, J, 751
Hakomori, S-i, 97
Hamaguchi, T, 279
Hampel, A, 513
Hansen, M, 833
Hariharan, M, 105
Harper, JD, 119, 951
Hassig, CA, 783
Hautala, A, 751

Head, MS, 87
Hegg, LA, 619
Herbert, CB, 731
Hess, WM, 529
Holderman, MT, 659
Hoffman, DC, 833
Holman, GM, 105
Holtz, KM, 489
Hope, T, 335
Hou, Y-M, 93
Hsiao, K, 423
Hypolite, CL, 731
Huang, CC, 731
Huang, H, 757
Hurwitz, LM, 711
Hunt, J, 845
Hu, WS, 731

Jacobsen, JR, 757
Jackman, RJ, 969
Johnson, DL, 939
Jain, RK, 63
Jolliffe, LK, 939
James, KD, 595
Janssen, RC, 675
Jiang, L, 35

Kao MC, 667
Kantola, J, 751
Kantrowitz, ER, 489
Kasianowicz, JJ, 497
Kayyem, JF, 519
Keller, U, 223
Kent, SBH, 187
Klens A, 927
Khosla, C, 667, 757
Kick, EK, 297
Kliewer, SA, 909
Kunnari, T, 751
Krom D, 939
Kreevoy, MM, 259
Koch, KA, 549
Kool, ET, 919
Konz, D, 927
Kozarich, JW, 373
Ku, J, 203
Kuntz, ID, 297
Kwon, DS, 859

Lambalot, RH, 17
Lane, WS, 693
Lansbury, PT, Jr, 119, 951
Lee, JA, 845

- Lehmann, JM, 909
Lester, HA, 739
Letourneau, PC, 731
Liberles, SD, 961
Lieber, CM, 119, 519, 951
Li, T, 209
Liley, D, 717
Lin, CH, 817, 859
Liu, D, 919
Liu, DR, 685
Liu, G, 297
Liu, L, 203
Loeb LA, 889
Lui, SM, 373
Lu, R, 693
Lu, Y, 215
Lundberg, KM, 345
- MacCaffrey, PG, 423
Maguire, AJ, 507
Mahal, LK, 415
Malhorta, R, 543
Mantsala P, 751
Marahiel, M, 561, 927
Masuda, A, 279
Matschinsky, FM, 249
Matsushima, P, 195
McCaskill, JM, 25
McDaniel, R, 667
McLernon, TL, 731
McMahon, FJ, 939
McPherson, M, 757
Magliery, TJ
Meade, TJ, 519
Mendez, C, 751
Micura, R, 309
Milhauser, GL, 345
Mirmira, RG, 203
Moran, S, 919
Morino, T, 279
Mulcahy, 939
Murcko, MA, 423
Myers, JK, 489
- Nachman, RJ, 105
Nash, HM, 639
Nesbitt, S, 619
Nesse, F, 795
Nicholson, DW, 149
Nicolau, KC, 1, 209
Noy, A, 519
- Obst, U, 287
Orband Miller
Orgel, LE, 167
Osada, H, 279
- Pardi, A, 833
Parkis, DJ, 909
Patel, DJ, 35, 817
Pavel, E, 795
Pazhanisamy, S, 423
Pearson, ND, 409
Pena, M, 549
Peterson, EP, 149
Petillo, PA, 215
Pikus, L, 731
Potter, BVL, 51
Prendergast, K, 239
Prescott, CD, 409
Priyadarshy, S, 3
Prusiner, SB, 345
Pulver, SC, 389
- Rajski, SR, 127
Rano, TA, 149
Richert, C, 63
Riederer, B, 223
Risser, SM, 3
Roberts C, 899
Roberts, VA, 105
Roe, DC, 297
Roessner, CA, 659
Roger, YT, 867
Rollins, SB, 127
Rotonda, J, 149
- Sabeti, PC, 767
Salas, J, 751
Sanglier, J-J, 139
Santander, PJ, 659
Santi, DV, 203
Schreiber, SL, 1, 961, 969
Schroeder, R, 357, 783
Schorgendorfer, K, 927
Schultz, PG, 685
Scott, AL, 659
Sen, D, 579
Sennello, J, 809
Sethi, JK, 51
Shair, MD, 791
Shao, Y, 187
Shapiro, L, 637
Sigman, JA, 215
Skillman, AG, 197
Skandalis, A, 889
Smith, D, 809
Smith-Oliver, A, 909
Solenberg, PJ, 195
Solomon, E, 795
Song, L, 497
Stec, B, 489
Stephen, C, 637
- Sternbach, dd, 909
Stolowich, NJ, 659
Streicher, B, 357
Strobel, GA, 529
Siuzdak, G, 653
Sun, Y, 297
Suri, AK, 35
Sutherland, JD, 481
Su, M, 423
Stack, DR, 195
Steinbeck, C, 63
Stenland, CJ, 345
Stemp, E, 389
Stubbe, J, 373
Switzer, 899
Szostak, JW, 607
- Tainer, JA, 105
Takayama, S, 653
Tauton, J, 493
Tetzlaff, C, 63
Thiele, D, 549
Thompson, RC, 195
Thornberry, NA, 149
Timkey, T, 149
Tomkinson, CO, 909
Tong, JK, 783
Townsend, CA, 721
Trono, D, 13
Tsien, RY, 269
Tsuzuki, W, 507
Tullai, J, 939
Turner, CJ, 373
- Underwood, DJ, 239
Unrau, PJ, 767
- Vanderwall, DE, 373
Varda, LR, 867
Verdine, GL, 329, 693
Vezenov, DV, 519
Vogel, KW, 17
- Wade, LE, 909
Wagenknecht, HA, 367
Walker, B, 497
Wallace, ST, 357
Wallis, MG, 357
Walsh, CT, 17, 859
Walzel, B, 223
Wang, J-K, 13
Wang, Y, 139
Wang, X, 215
Wank, H, 357
Webber, L, 287
Weinstein, DS, 209

Wells, WA, 79, 157, 231, 321,
401, 473, 537, 631, 703, 775,
879, 977

White, S, 569

Whitesides, GM, 969

Wiegand, TW, 675

Widlanski, TS, 489

Wilkie, SC, 195

Williams, DH, 507

Williams, H, 105

Williams, RM, 127

Wilson, KP, 423

Wilson, TM, 909

Wolff, B, 139

Wong, CH, 653

Wlotzka, B, 25

Woggon, WD, 367

Wong, SS, 119

Wu, J, 653

Yeung, BKS, 215

You, 969

Ylihonko, K, 751

Zhang, Y, 97

Zhou, J, 795

Zivin A, 939

Subject index

Volume 4 1997

The letters in parentheses refer to the following: X = Crosstalk, M = Minireview, R = Review, P = Research paper, I = Innovations

- A β -amyloid protofibrils, 119 (P), 951 (P)
- Abbott Laboratories, 231 (I)
- Active-site structure of lipoxygenases, 795 (R)
- Acyl carrier proteins
 - as substrates for holo-ACP synthase, 17 (P)
- Alkaloid cyclopeptide synthesis, 223 (P)
- Affymax N.V., 79 (I)
- Agonist
 - Ca²⁺-mobilizing, 51 (P)
 - of erythropoietin receptor, 939 (P)
 - 7-deaza cyclic adenosine 5'-diphosphate ribose, 51 (P)
- Alkylation
 - of DNA and inosine substituents, 127 (P)
- Alzheimer's disease
 - observation of assembly intermediates, 119 (P)
 - observation of protofibril formation, 951 (P)
- Amino acids, as insulin stimulants, 249 (R)
- Aminoacylation of tRNA, 93 (M), 685 (P)
- Amphiporphyrins, decomposition of peroxytrite by, 845 (P)
- Amyloid
 - brain amyloid plaques and observation of A β -amyloid protofibrils, 119 (P), 951 (P)
 - formation by the prion protein H1 peptide, 345 (P)
- AMP, complex with DNA, 817 (P)
- Angiogenesis, 461 (P), 493 (M)
- Antibiotics
 - aminoglycoside antibiotic-RNA complex, 35 (P)
 - anthracycline, 751 (P)
 - antitumor, FR90082, DNA cross-linking, 127 (P)
 - bacterial protein secretion as a target for, 637 (X)
 - chloramphenicol binding to RNA, 833 (P)
 - erythromycin, 667 (P)
 - interactions with RNA, 357 (P), 833 (P)
 - measurement of two-state analysis using, 507 (P)
 - mithramycin, 751 (P)
 - nonribosomal biosynthesis of, 561 (R)
 - peptide templates for, 561 (R)
 - production of hybrid glycopeptide antibiotics, 195 (P)
 - resistance, 637 (X)
 - vancomycin, 195 (P), 507 (P)
 - viomycin-binding RNA, 357 (P)
- Antigens
 - of glycosphingolipids, 97 (R)
- Antitumor agents
 - aromatic polyketide antibiotics, 751 (P)
 - bleomycins, 373 (P)
- FR90082, 127 (P)
- Antiviral therapy
 - RNA export and, 335 (R)
- Aptamer of ATP, 453 (P), 607 (P)
- Aptamer inhibitor of elastase, 809 (P)
- Arrayed nanodroplets, to screen small molecules, 969 (P)
- Aromatic polyketide synthesis, 751 (P)
- Atomic force microscopy
 - to observe A β -amyloid protofibrils, 119 (P), 951 (P)
- Aurora Biosciences Corporation, 537 (I)
- Azid-1, a calcium chelator, 867 (P)
- Bacillus licheniformis*, 927 (P)
- Bacitracin
 - biosynthesis operon for, 927 (P)
- Bacterial protein secretion, 637 (X)
- Base
 - excision repair, 329 (X), 693 (P)
 - mismatch pairs, oxidation of, 389 (P)
- β -cells and fuel homeostasis, 249 (R)
- Bending, of DNA, 643 (R)
- Binding affinities, 87 (X)
- Biocytin, incorporation into membrane proteins, 739 (P)
- Biosensors
 - structure-based design of, 497 (P)
- Biotechnology
 - Affymax N.V., 79 (I)
 - Abbott Laboratories, 231 (I)
 - Aurora Biosciences Corporation, 537 (I)
 - Dyax Corporation, 977 (I)
 - Geron Corporation, 879 (I)
 - Millenium Pharmaceuticals, 473 (I)
 - Mitotix, Inc, 631 (I)
 - Ontogeny, Inc, 703 (I)
 - Pharmacyclics, Inc., 775 (I)
 - Recombinant Biocatalysis, Inc., 401 (I)
 - Synteni Inc., 157 (I)
 - Xenometrix, Inc., 321 (I)
- Biotinylated amino acids, incorporation into membrane proteins, 739 (P)
- Bonds, short strong hydrogen, 259 (R)
- Butyrate, 783 (X)
- Calcium
 - caged, azid-1, 867 (P)
 - control of, using chelators, 867 (P)
 - mobilization, 51 (P)

Cancer

- metastasis, 493 (M)
- therapy, glycosphingolipid antigens, 97 (R)
- therapy, histone deacetylase inhibitors, 783 (X)
- therapy, photodynamic therapy, 775 (I)
- therapy, prenylcysteines, 711 (X)
- therapy, cyclin inhibitors, 631 (I)
- tumor growth and angiogenesis, 461 (P)

Cardiovascular disease, 473 (I)

Caspase-1/ICE, specificity of, 149 (P)

Catalytic DNA, 579 (P)

Catalytic mechanism

- of alkaloid peptide synthesis, 223 (P)
- of chloroperoxidase, 367 (P)
- of DNAglycylsylase/lyase, 693 (P)
- role of short strong hydrogen bonds in, 259 (R)

Catalytic RNA, 607 (P), 619 (P), 675, (P), 767 (P)

CDKs, 631 (I)

Cell cycle

- arrest, p53 and, 791 (M)
- effect of stevastelins on, 279 (P)
- regulation of, 631 (I)

Cell division, 631 (I)

Cell membrane potentials, detection of, 269 (P)

Cell shape, control of on self-assembled monolayers, 731 (P)

Cell surface

- engineering of, 415 (R)
- interaction with environment, 415 (R)

Cellular damage, assays for, 321 (I)

Chelators, photolabile, to control calcium levels, 867 (P)

Chemical force microscopy

- to study DNA duplex structure, 519 (P)

Chemical libraries

- for design of inhibitors, 297 (P)
- for design of peroxisome proliferator-activated receptor ligands, 909 (P)
- mass spectrometry of, 63 (P), 653 (P)
- positional scanning, 149 (P)

Chemical ligation (versus enzymatic ligation) of oligonucleotides, 595 (P)

Chiroselectivity, origin of homochirality, 309 (P)

Chloramphenicol, complexed with RNA, 833 (P)

Chromatography, 977 (I)

Cobalamin biochemistry, 175 (R)

Coenzyme A

- analogs as substrates for holo-ACP synthase, 17 (P)

Combinatorial chemistry

- Affymax N.V., 79 (I)
- and construction of biased chemical libraries, 909 (P)
- and design of phosphatase inhibitors, 489 (M)
- and identification of ligands for peroxisome proliferator-activated receptors, 909 (P)

and use in design of biosensors, 497 (P)

for polyketide synthesis, 757 (P)

screening libraries produced by, 961 (P), 969 (P)

to determine protease specificity, 149 (P)

to produce cathepsin D inhibitors, 297 (P)

Copper

binding motifs in catalysis, 549 (R)

effect on RNA catalyst, 675 (P)

enzymes dependent on, 549 (R)

transport of, 549 (R)

Coupled systems

for studying coevolution, 25 (P)

Cre-lox complex, 717 (M)

Cyclins, 631 (I)

Cyclopeptide synthesis, mechanism of, 223 (P)

Cystic fibrosis therapy, 977 (I)

Diabetes and control of insulin release, 249 (R)

Diketide analogs, 757 (P)

Difluorotoluene

and poor hydrogen bonding ability, 919 (P)

replacement as thymidine, 919 (P)

Dimerization

as a method to increase ligand potency, 939 (P)

of antibiotics, two-state analysis of, 507 (P)

DNA

AMP binding to, 817 (P)

bending, 643 (R)

binding forces of duplex, 519 (P)

bleomycin binding to, 373 (P)

cDNA clones on glass chips, 157 (I)

chemical end-ligation within a triple helix, 209, (P)

cloning, 167 (X)

cross linking, mitosene-based, 127 (P)

damage and p53, 791 (M)

elastic properties of duplex, 519 (P)

electron transfer reactions involving, 3 (X), 389 (P)

elongation forces of duplex, 519 (P)

elongation in evolution, 209 (P)

folding and recognition, 817 (P)

glycosylases, 329 (X)

importance of nucleotide shape for duplex stability, 919 (P)

minor groove recognition, 569 (P)

oligomers involved in origin of life, 209 (P)

oxidative damage of, 389 (P)

recognition and bending, 643 (R)

recombination, Cre-lox complex, 717 (M)

repair, 329 (X), 389 (P), 693 (P)

separable orientation isomers, 127 (P)

structure of duplex, 519 (P)

DNA sequencing

Maxam-Gilbert, 919 (P)

method for detecting difluorotoluene

DNAzyme

that cleaves RNA, 579 (P)

- metal cofactor dependence of, 579 (P)
 importance of structural features during catalysis, 579 (P)
- Drug discovery,
 mass spectrometry of chemical libraries towards, 63 (P)
 using NMR, 231 (I)
 use of cDNA clones on glass chips in, 157 (I)
- Drug design
 bacterial protein secretion and, 637 (X)
 of phosphate inhibitors, 489 (M)
 peroxynitrite decomposers, 845 (P)
 prenylcysteines, 711 (X)
 using RNA, 409 (X)
- Drug discovery
 using RNA, 409 (X)
- Drug resistance, 711 (X)
- Dyax Corporation, 977 (I)
- Earth, life on, clues from Mars, 9 (M)
- Elastase, inhibitor of, 809 (P)
- Electron microscopy
 to study amyloid formation, 345 (P)
- Electron spin resonance
 to study amyloid formation, 345 (P)
- Electron transfer reaction involving DNA, 3 (X), 389 (P)
- Electrospray mass spectrometry, 653 (P)
- Endophytic fungus
 and relationship with yew tree, 529 (P)
- Energetics
 of short, strong hydrogen bond formation, 259 (R)
- Enzyme catalysis
 role of short, strong hydrogen bonds in, 261 (R)
- Enzymes
 AlkA, 329 (X)
 aminoacyl-tRNA synthetase, 685 (P)
 CbiH, 659 (P)
 chloroperoxidase, 367 (P)
 cytochrome c peroxidase, 215 (P)
 D-lysergyl peptide synthetase, 223 (P)
 DNA glycosylase/lyase, 693 (P)
 elastase, inhibition of, 809 (P)
 endonuclease III, 329 (X)
 galactosyltransferase, screening of inhibitors of, 653 (P)
 glycosyltransferases, to produce hybrid compounds, 195 (P)
 glucokinase as a glucose sensor, 249 (R)
 glutathionylspermidine synthase/amidase, 859 (P)
 interleukin-1 β converting enzyme (ICE), 149 (P)
 isopenicillin N synthase, 721 (R)
 lipoxygenases, 795 (R)
 methionine synthase, 175 (R)
 methylmalonyl-CoA mutase, 175 (R)
 microbial dehalogenation of aromatic compounds, 169 (M)
 models, of heme-thiolate proteins, 367 (P)
 non-ribosomal peptide synthetases, 203 (P)
 phosphopantetheinyl transferase, 203 (P)
 polyketide synthases, 667 (P), 721 (R), 751 (P), 757 (P)
- Enzymatic synthesis
 in vitamin B12 synthesis, 445 (P)
- Ergot alkaloid peptide synthesis, 223 (P)
- Erythropoietin
 receptor of, 939 (P)
 role in red blood cell production, 939 (P)
 peptide mimetics of, 939 (P)
 improving potency of peptide mimetics, 939 (P)
- Evolution
 coevolution studies, 25 (P)
in vitro, predator-prey systems, 25 (P)
 of RNA, 309 (P), 675 (P)
 self-replicating nucleotides in chemical evolution, 209 (P)
- Fatty acids, as insulin stimulants, 249 (R)
- Ferrous lipoxygenases, 795, (R)
- Fibrate
 as a biasing monomer in the design of a chemical library, 909 (P)
- Fibrils
 Ab-amyloid, 119 (P)
- Fluorescence resonance energy transfer, 269 (P), 537 (I)
- Fluorescent detector, 537 (I)
- G.A mismatched base pair
 forms readily in the absence of oligonucleotide replication enzymes, 595 (P)
- General secretory pathway, 637 (X)
- Gene regulation, and role of minor groove, 569 (P)
- Genetic engineering
 synthesis of bioactive peptides, 203 (P)
 production of antibiotics by, 195 (P)
- Genome
 analysis of, 157 (I)
 cloning of, 167 (X)
- Geron Corporation, 879 (I)
- Glutathione, conversion to glutathionyl spermidine, 859, (P)
- Glutathionylspermidine synthase/amidase, 859, (P)
- Glycopeptide antibiotics, production of, 195 (P)
- Glycosphingolipids, antigens of, 195 (P)
- Green fluorescent protein, 537 (I)
- Halogenation
 by chloroperoxidase, 367 (P)
- Heme-thiolate proteins, 367 (P)
- High-throughput screening, 961 (P)
- Histone deacetylase, 783 (X)
 inhibitors of, 783 (X)

- Holliday junction, site-specific recombination, 717 (M)
Homochirality, the origin of, 309 (P)
Human immunodeficiency virus (HIV)
 influence of Nef on, 13 (M)
 inhibiting nuclear export of HIV-1 Rev protein, 139 (P)
Human neutrophil elastase, inhibitor of, 977 (I)
Hydrogen bonds, short strong, 259 (R)
Hydrogen bonding
 importance in DNA helix structure, 919 (P)
 comparison of difluorotoluene and thymine, 919 (P)
- Imaging of inflammation, 809 (P)
Immunosuppressants
 stevastelin B, 279 (P)
Intermediates in B₁₂ biosynthesis, 659 (P)
In vitro selection
 of a ligase ribozyme, 607 (P)
 to identify RNA that binds chloramphenicol, 833 (P)
 to isolate RNA from large pools, 767 (P)
 to isolate catalytic RNA, 675 (P), 767, (P)
In vivo imaging, 809 (P)
In vivo suppression, incorporation of amino acids using, 739 (P)
In vivo unnatural amino acid mutagenesis, 685
- Inhibition
 of cathepsin D, 297 (P)
 of galactosyltransferase, screening for, 653 (P)
 of histone deacetylase, 783 (X)
 of human neutrophil elastase, 809 (P), 977 (I)
 of methionine aminopeptidase, type 2, 461 (P), 493 (M)
 of multidrug resistance transporters, 711 (X)
 of phosphatases, 489 (M)
 of protein phosphatases, 279 (P)
 of RNA function by viomycin, 357 (P)
 of telomerase, 879 (I)
 of thrombin, 287 (P)
- Insect kinins, compounds for insect control, 105 (P)
Insulin release and fuel homeostasis, 249 (R)
Inteins, protein splicing, 187 (R)
Interleukin-1 β converting enzyme, specificity of, 149 (P)
Isomers
 orientation, DNA cross linking, 127 (P)
Isothermal amplification
 for studying coevolution, 25 (P)
- Leptin receptor, 473 (I)
Leptomycin B
 inhibits nuclear export of HIV-1 Rev protein and Rev-dependent mRNA, 139 (P)
Leukocytes
 role in septic shock, 543 (X)
Leucinostatin A toxicity, 529 (P)
Life on Earth, 9 (M)
- Ligand design for G protein coupled receptors, 239 (X)
Ligands, screening in stochastic nanodroplets, 961 (P)
Lipids
 glycosphingolipids and cancer, 97 (R)
Lipopolysaccharide
 as a receptor for L-selectin, 543 (X)
 role in septic shock, 543 (X)
Liposomes
 for delivery of amphiporphyrins, 845 (P)
 sterically stabilized, 845 (P)
Lipoxygenases, 795 (R)
L-selectin
 role in septic shock, 543 (X)
- Magnesium
 role in ribozyme mechanism, 513 (P)
Manganese-binding site in cytochrome c peroxidase, 215 (P)
MAP kinase, p38
 specific inhibitors of, 423 (P)
 pyridinylimidazole inhibitors of, 423 (P)
 structural basis of inhibition of, 423 (P)
Mars, life on, 9 (M)
Mass spectrometry
 selection experiments of chemical libraries, 63 (P)
Mdm2-p53 complex, 791 (M)
Membrane
 potential, detection of, 269 (P)
 proteins, incorporation of unnatural amino acids into, 739 (P)
 self-assembly, 845 (P)
Metalloporphyrins, decomposition of peroxyxynitrite by, 845 (P)
Metalloproteins
 manganese-binding site in cytochrome c peroxidase, 215 (P)
Metals
 copper, effect on ribozyme affinity, 675 (P)
 manganese-binding site in cytochrome c peroxidase, 215 (P)
Metastasis, 493 (M)
Meteorite from Mars, 9 (M)
Methionine aminopeptidase, type 2,
 inhibitors of, 461 (P), 493 (M)
Micropatterns of bioactive molecules, 731 (P)
Microscopy
 atomic force, 119 (P), 951 (P)
 chemical force, 519 (P)
 electron, 345 (P)
Millenium Pharmaceuticals, 473 (I)
Mitochondria
 implications of cloning, 167 (X)
Mitomycin C
 exploiting DNA cross linking, 127 (P)
Models
 for computing binding affinities, 87 (X)

- for signal transduction, 239 (X)
 - for studying coevolution, 25 (P)
 - of bleomycin–DNA, 373 (P)
- Molecular design
 - involved in design of biosensors, 497 (P)
- Molecular ecology
 - predator–prey systems, 254 (P)
- Molecular recognition,
 - and use in design of biosensors, 497 (P)
 - of AMP by DNA, 817 (P)
 - of bleomycin by DNA, 373 (P)
 - of chloramphenicol by RNA complex, 833 (P)
 - of diketide substrates by polyketide synthase domain, 757 (P)
 - of DNA's minor groove, 569 (P)
 - of p53 by Mdm2, 791 (M)
 - of substrate by RNA catalysts, 675 (P)
 - of thrombin, 287 (P)
 - of tobramycin by RNA, 35 (P)
 - of viomycin by RNA, 357 (P)
- Multidrug resistance, 711 (X)
- Multidrug resistance transporters, 711 (X)
- Mutagenesis, of 8-oxoguanine DNA glycosylase, 693 (P)
- Nanodroplets, screening ligands using, 961 (P), 969 (P)
- Natural products
 - actinorhodin, 433 (P)
 - AGM-1470, 461 (P), 493 (M)
 - angucyclines, 433 (P)
 - bacitracin, 927 (P)
 - bleomycins, 373 (P)
 - daunorubicin, 433 (P)
 - epoxide containing, 493 (M)
 - fumagillin, 461 (P), 493 (M)
 - jadomycin B, 433 (P)
 - leptomycin B, 139 (P)
 - leucinostatin A, 529 (P)
 - microbial dehalogenation, 169 (M)
 - ovalicin, 461 (P)
 - stevastelin B, 279 (P)
 - synthesis of, 721 (R)
 - tetracenomycin C, 433 (P)
 - vancomycin, 195 (P)
 - viomycin, 357 (P)
 - vitamin B₁₂, 445 (P)
- Nef
 - association with PAK, 13 (M)
- Neuropeptide
 - family, active core conformation, 105 (P)
 - Neuropeptide Y, 473 (I)
- Neutrophil elastase for imaging inflammation, 809 (P)
- Neutrophils
 - role in septic shock, 543 (X)
- Nuclear export signals, 335 (R)
- Nuclear magnetic resonance (NMR)
 - a beginner's guide, 231 (I)
 - of AMP–DNA complexes, 817 (P)
 - of bleomycin–DNA complexes, 373 (P)
 - to determine active core conformation of neuropeptides, 105 (P)
 - paramagnetic, use of, to determine manganese-binding sites 215 (P)
- Nuclear receptors
 - identifying ligands for, 909 (P)
- Nucleic acids
 - chemical end-ligation of nucleotides, 209 (P)
 - in controlling gene expression, 209 (P)
 - interacting systems for coevolution studies, 25 (P)
- Nucleoside analogs
 - difluorotoluene, 919 (P)
- Nucleotides
 - chemical end-ligation of, 209 (P)
 - discriminator bases of tRNAs, 93 (M)
 - influence on DNA bending, 643 (R)
- Oligo(ethylene glycol) alkanethiolates, self-assembled monolayers of, 731 (P)
- Oligonucleotides
 - end-ligation on a triple helix, 209 (P)
 - ligation of homochiral, 309 (P)
- Oligomerization of homochiral tetramer cyclophosphates, 309 (P)
- Oncoprotein–tumor suppressor interaction, 791 (M)
- Ontogeny, Inc., 703 (I)
- Organometallics, cobalamin biochemistry, 175 (R)
- Organic molecules
 - evolution of, 9 (M)
 - chlorination of aromatic compounds, 169 (M)
- Origins of life
 - homochirality, the origin of, 309 (P)
 - isolation of a ligase ribozyme, 607 (P)
 - model links nucleic acid replication and coded peptide synthesis, 481 (X)
 - self replication (chemical ligation) of oligonucleotides, 595 (P)
- Orphan receptors
 - identifying ligands for, 909 (P)
- 8-Oxoguanine DNA glycosylase, 693 (P)
- Oxonol in detecting cell membrane potentials, 269 (P)
- p53–Mdm2 complex, 791 (M)
- PAK family of protein kinases, 13 (M)
- Pancreatic β -cells and fuel homeostasis, 249 (R)
- Pathways
 - nuclear export, inhibition of HIV-1 Rev translocation, 139 (P)
 - signaling pathway of cADPR, design of modulators, 51 (P)
 - vitamin B₁₂ biosynthesis, 659 (P)
- Penicillin, synthesis of, 721 (R)

- Peptide aggregates
 amyloid formation and, 345 (P)
- Peptide alkaloid synthesis, 223 (P)
- Peptide antibiotics, 927 (P)
- Peptide, photoimmobilization of, 731 (P)
- Peptide synthetases
 for bacitracin, cloning of, 927 (P)
 crystal structure of adenylation domain, 561 (R)
 modules of, 561 (R)
 non-ribosomal, 203 (P)
 substrate recognition by, 561 (R)
 substrate activation by, 561 (R)
- Peptide therapeutics, 977 (I)
- Peroxisome proliferator-activated receptors
 ligands for, 909 (P)
- Peroxynitrite, decomposition of, 845 (P)
- Phage display, 977 (I)
- Pharmacyclics, Inc., 775 (I)
- Phosphatase
 inhibitors of, 489 (M)
- Phospholipids
 in detecting cell membrane potentials, 269 (P)
- Photoactivatable peptides, 731 (P)
- Photochemical, mechanism of azid-1, 867 (P)
- Photoimmobilization of bioactive molecules, 731 (P)
- Photolysis of azid-1, 867 (P)
- Polyamides (pyrrole-imidazole)
 involvement in minor groove recognition, 569 (P)
- Polyethylene glycol
 as a dimerizing agent, 939 (P)
 use in dimerizing erythropoietin mimetic peptides,
 939 (P)
- Polyketides
 synthesis of, 433 (P), 667 (P), 721 (R), 751 (P)
- Polyketide synthase, 433 (P), 667 (P), 751 (P), 757 (P)
 type II, 433 (P)
 hybrid systems of, 433 (P)
 combinatorial expression of, 433 (P)
- Porphyrin
 libraries, selection experiments on, 63 (P)
- Prenylcysteines, inhibition of drug-transporting proteins by, 711 (X)
- Prion protein
 amyloid formation by, 345 (P)
- Proteases
 cathepsin D, design of inhibitors of, 297 (P)
 determining specificity of, 149 (P)
 interleukin-1 β converting enzyme, 149 (P)
 thrombin, design of inhibitors of, 287 (P)
- Protein assembly
 β -amyloid formation, 119 (P), 951 (P)
- Protein engineering
 DNA glycosylase/lyase, 693 (P)
 polyketide synthases, 667 (P)
 towards a novel manganese peroxidase, 215 (P)
- Protein–ligand interactions, detection of, 961 (P)
- Protein–nucleic acid interactions
 Cre–*lox* complex, 717 (M)
 DNA recognition and bending, 643 (R)
- Protein kinases
 association of Nef with, 13 (M)
- Protein–protein interactions
 p53–Mdm2, 791 (M)
- Protein secretion, 637 (X)
- Protein splicing, 187 (R)
- Protein synthesis
 aminoacylation of tRNAs, 93 (M), 685 (P)
- Protein tyrosine phosphatase, effect of stevastatin on,
 279 (P)
- Pyranosyl-RNA, chiroselective self-assembly of base
 sequences, 309 (P)
- Radical
 migration through DNA, 389 (P)
- Receptor activation
 mechanism of, 939 (P)
 dimerization as an activation mechanism, 939 (P)
- Receptors
 binding determination towards core conformation,
 105 (P)
 G protein coupled, 239 (X)
 –ligand binding affinities, 87 (X)
 nicotinicacetylcholine, incorporation of amino
 acids into, 739 (P)
- Recognition
 of DNA–protein after cross linking and restriction
 digest of DNA, 127 (P)
 in an antibiotic–RNA complex, 35 (P)
 saccharide–RNA, 35 (P)
- Recombinant Biocatalysis, Inc., 401 (I)
- Recombination, site-specific, 717 (M)
- Regulation
 of insulin release, 249 (R)
 Rev, regulatory protein of HIV-1, 139 (P)
- Ribose,
 7-Deaza cyclic adenosine 5'-diphosphate, 51 (P)
- Ribozymes
 hairpin ribozyme cleavage, 513 (P), 619 (P)
 mechanism of, 513 (P)
 rational design of allosteric ribozyme, 453 (P)
 regulation by ATP, 453 (P)
 RNA amide synthases, 675 (P)
 selection of, 767 (P)
 that ligates AMP-activated RNA substrates, 607
 (P)
- RNA
 amide synthases, 675 (P)
 as a drug target, 409 (X)
 binding by HIV-1 Rev, 335 (R)
 binding by chloramphenicol, 833 (P)
 catalytic, 767 (P), 675 (P)
 export in viruses, 335 (R)

- folding, 767 (P)
 isolation of, effect of sequence length, 767 (P)
 Rev dependent mRNA, inhibiting nuclear export of, 139 (P)
 protein splicing vs RNA splicing, 187 (R)
 pseudoknots, 357 (P)
 pyranosyl, 309 (P)
 saccharide–RNA recognition, 35 (P)
 suppressor tRNA, 685 (P)
 tRNA discriminator bases, 93 (M)
 viomycin-binding, 357 (P)
 with rare activities, isolation of, 767 (P)
- RNA catalysis**
 amide synthases, 675 (P)
 cobalt hexamine involvement in, 619 (P)
 ligation of AMP-activated RNA substrates, 607 (P)
 metal-ion independent, 619 (P)
 pH independent mechanism, 619 (P)
- Saccharides**
 lipopolysaccharide, 543 (X)
 saccharide–RNA recognition, 35 (P)
- Screening compounds synthesized by split-pool synthesis, 961 (P), 969 (P)**
- Secretion, of proteins, 637 (X)**
- Selective inhibitors of glutathionylspermidine synthase/amidase, 859, (P)**
- Self-assembled monolayers, 731 (P)**
- Self-replication of oligonucleotides, 595 (P)**
- Signaling pathway**
 of cADPR, design of modulators, 51 (P)
- Signal transduction**
 and design of phosphatase inhibitors, 489 (M)
 in G protein coupled receptors, 239 (X)
 kinin neuropeptide activity and, 105 (P)
- Site-specific incorporation of unnatural amino acids, 739 (P)**
- Slow-binding inhibition of glutathionylspermidine synthase/amidase, 859, (P)**
- Solid phase synthesis of chemical libraries, 909 (P)**
- Spectroscopy, properties of lipoxygenases measured by, 795 (R)**
- Stevastelins as inhibitors of protein phosphatases, 279 (P)**
- Structure-based design**
 of cathepsin D inhibitors, 297 (P)
 of thrombin inhibitors, 287 (P)
- Structure**
 β -turn conformation of neuropeptide active cores, 105 (P)
 of AMP bound to a DNA aptamer, 817 (P)
 of bleomycin bound to DNA, model of, 373 (P)
 of Cre bound to *lox*, 717 (M)
 of lipoxygenases, 795 (R)
 of natural product biosynthetic proteins, 721 (R)
 of p38 MAP kinase inhibitors, 423 (P)
- of p53 bound to Mdm2, 791 (M)
 of ribosomal RNA, 833 (P)
- Suppressor tRNA, characterization of, 685, (P)**
- Surface exposure in membrane proteins, 739 (P)**
- Symbiosis,**
- Synthases**
E. coli holo acyl carrier protein synthase, 17 (P)
 methionine synthase, 175 (R)
- Synthesis**
 of cyclopeptides, 223 (P)
 of polyketides, 667 (P), 751 (P), 757 (P)
 of stevastelins, 279 (P)
 of thrombin inhibitors, 287 (P)
- Synthetases**
 aminoacyl-tRNA selecting target RNA, 93 (M)
 D-lysergyl peptide synthetase, 223 (P)
 expression of a functional non-ribosomal peptide synthetase, 203 (P)
 polyketide, 667 (P), 751 (P), 757 (P)
 tRNA synthetase, 93 (M)
- Synteni Inc., 157 (I)**
- Targeting**
 of glycoproteins and glycolipids, 415 (R)
- Telomerase, inhibition of, 879 (I)**
- Terpenes, synthesis of, 721 (R)**
- Therapies**
 cancer
 glycosphingolipid antigens and, 97, (R)
 multidrug resistance transporters and, 711 (X)
 inhibiting nuclear export of HIV-1 Rev protein, 139 (P)
 mitochondrial replacement, 167 (X)
 observation of intermediates of brain amyloid plaques in Alzheimers disease, 119 (P)
 use of amphiporphyrins, 845 (P)
- Thiazole ring, enzymatic synthesis of, 927 (P)**
- Thymine**
 replacement by difluorotoluene in DNA, 919 (R)
- Toxicity**
 of drugs, testing of, 321 (I)
 of leucinoastatin A, 529 (P)
- Transcription**
 of p21, regulation by histone deacetylase, 783 (X)
- Transitions, between disordered and weakly ordered states, 507 (P)**
- Translation**
 discriminator bases in tRNAs, 93 (M)
- Triple helix, end-ligation of oligomers, 209 (P)**
- Tumor growth**
 and angiogenesis, 461 (P),
- Tumor metastasis**
 glycosphingolipids and, 97 (R)
- Ultra high-throughput screening, 537 (I)**

UV spectroscopy,
to identify intermediates in the catalytic cycle of
chloroperoxidase, 367 (P)

Vancomycin, 195 (P), 507 (P)

Viomycin-binding RNA, 357 (P)

Virulence factor, Nef, 13 (M)

Viruses

RNA export and, 335 (R)

Voltage-sensitive FRET, 269 (P)

Xenometrix Inc., 321 (I)

X-ray crystal structure

comparison of, towards novel manganese
peroxidase, 215 (P)

of p38 MAP kinase inhibitors, 423 (P)

of thrombin-inhibitor complexes, 287 (P)

Yew tree and endophytic fungus, 529 (P)